Skip to main content
Top
Published in: BMC Nephrology 1/2017

Open Access 01-12-2017 | Research article

Vitamin E protects against extraskeletal calcification in uremic rats fed high fat diets

Authors: Rafael Rios, Ana I. Raya, Carmen Pineda, Mariano Rodriguez, Ignacio Lopez, Escolastico Aguilera-Tejero

Published in: BMC Nephrology | Issue 1/2017

Login to get access

Abstract

Background

High fat diets are implicated in the pathogenesis of metabolic syndrome, obesity and renal disease. Previous studies have revealed that high fat diets promote vascular calcification in uremic rats. Moreover, vitamin E has been shown to prevent uremic calcifications in genetically obese Zucker rats fed standard diet. The objective of this study was to investigate the influence of vitamin E supplementation on the development of extraskeletal calcifications in non-obese (wild type) uremic rats fed high fat diets.

Methods

Wistar rats (n = 32) were preconditioned by feeding either a normal (NF) or high fat (HF) diet for 45 days and subsequently were subjected to 5/6 nephrectomy (Nx). Just before performing the first Nx step, a blood sample (Pre-Nx) was obtained. After Nx rats were switched to a diet with 0.9% phosphorus and supplemented with calcitriol. Also, after Nx, half of the rats from each group (NF and HF) were treated with vitamin E (VitE) in the diet (30,000 mg/kg) and the other half were maintained on basic VitE requirements (27 mg/kg). Thus, rats were allotted to four experimental groups: Nx-NF (n = 8), Nx-NF-VitE (n = 8), Nx-HF (n = 8) and Nx-HF-VitE (n = 8). At the time of sacrifice (day 66), blood and tissue samples were obtained.

Results

Feeding a HF diet for 45 days did not increase body weight but elicited hyperglycemia, hypertriglyceridemia, an increase in plasma fibroblast growth factor 23 and a reduction in plasma calcitriol concentrations. After Nx, rats fed HF diet showed substantial extraskeletal calcification with aortic calcium content that was higher than in rats fed NF diet. Supplementation with VitE significantly (p < 0.05) reduced aortic (from 38.4 ± 8.8 to 16.5 ± 1.4 mg/g), gastric (from 5.6 ± 2.7 to 1.2 ± 0.4 mg/g) and pulmonary (from 1.8 ± 0.3 to 0.3 ± 0.2 mg/g) calcium content in rats on HF diets.

Conclusions

Uremic rats fed HF diets developed more severe extraosseous calcifications than their normocaloric-fed counterparts and dietary VitE supplementation protected against uremic calcifications in rats fed HF diets. Thus, eating energy-rich foods should be discouraged in patients with renal disease and their deleterious effect may be ameliorated with adequate antioxidant supply.
Literature
1.
go back to reference Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378:815–25.CrossRefPubMed Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378:815–25.CrossRefPubMed
2.
go back to reference Salazar-Martinez E, Allen B, Fernandez-Ortega C, Torres-Mejia G, Galal O, Lazcano-Ponce E. Overweight and obesity status among adolescents from Mexico and Egypt. Arch Med Res. 2006;37:535–42.CrossRefPubMed Salazar-Martinez E, Allen B, Fernandez-Ortega C, Torres-Mejia G, Galal O, Lazcano-Ponce E. Overweight and obesity status among adolescents from Mexico and Egypt. Arch Med Res. 2006;37:535–42.CrossRefPubMed
3.
go back to reference Gonzalez-Bulnes A, Astiz S, Ovilo C, Garcia-Contreras C, Vazquez-Gomez M. Nature and Nurture in the Early-Life Origins of Metabolic Syndrome. Curr Pharm Biotechnol. 2016;17:573–86.CrossRefPubMed Gonzalez-Bulnes A, Astiz S, Ovilo C, Garcia-Contreras C, Vazquez-Gomez M. Nature and Nurture in the Early-Life Origins of Metabolic Syndrome. Curr Pharm Biotechnol. 2016;17:573–86.CrossRefPubMed
4.
go back to reference Riccardi G, Giacco R, Rivellese AA. Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr. 2004;23:447–56.CrossRefPubMed Riccardi G, Giacco R, Rivellese AA. Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr. 2004;23:447–56.CrossRefPubMed
5.
go back to reference Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–74.CrossRefPubMed Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–74.CrossRefPubMed
6.
go back to reference Hall JE, Kuo JJ, da Silva AA, dePaula RB, Liu J, Tallam L. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens. 2003;12:195–200.CrossRefPubMed Hall JE, Kuo JJ, da Silva AA, dePaula RB, Liu J, Tallam L. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens. 2003;12:195–200.CrossRefPubMed
7.
go back to reference Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol. 2013;33:14–22.CrossRefPubMed Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol. 2013;33:14–22.CrossRefPubMed
8.
go back to reference Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–18.CrossRefPubMed Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–18.CrossRefPubMed
9.
go back to reference Peralta-Ramírez A, Montes de Oca A, Raya AI, Pineda C, López I, Guerrero F, Díez E, Muñoz-Castañeda JR, Martinez J, Almaden Y, Rodriguez M, Aguilera-Tejero E. Vitamin E protection of obesity-enhanced vascular calcification in uremic rats. Am J Physiol Renal Physiol. 2014;306:F422–9.CrossRefPubMed Peralta-Ramírez A, Montes de Oca A, Raya AI, Pineda C, López I, Guerrero F, Díez E, Muñoz-Castañeda JR, Martinez J, Almaden Y, Rodriguez M, Aguilera-Tejero E. Vitamin E protection of obesity-enhanced vascular calcification in uremic rats. Am J Physiol Renal Physiol. 2014;306:F422–9.CrossRefPubMed
10.
go back to reference Raya AI, Rios R, Pineda C, Rodriguez-Ortiz ME, Diez E, Almaden Y, Muñoz-Castañeda JR, Rodriguez M, Aguilera-Tejero E, Lopez I. Energy-dense diets increase FGF23, lead to phosphorus retention and promote vascular calcifications in rats. Sci Rep. 2016;6:36881.CrossRefPubMedPubMedCentral Raya AI, Rios R, Pineda C, Rodriguez-Ortiz ME, Diez E, Almaden Y, Muñoz-Castañeda JR, Rodriguez M, Aguilera-Tejero E, Lopez I. Energy-dense diets increase FGF23, lead to phosphorus retention and promote vascular calcifications in rats. Sci Rep. 2016;6:36881.CrossRefPubMedPubMedCentral
12.
go back to reference Villa-Bellosta R, Millan A, Sorribas V. Role of calcium-phosphate deposition in vascular smooth muscle cell calcification. Am J Physiol Cell Physiol. 2011;300:C210–20.CrossRefPubMed Villa-Bellosta R, Millan A, Sorribas V. Role of calcium-phosphate deposition in vascular smooth muscle cell calcification. Am J Physiol Cell Physiol. 2011;300:C210–20.CrossRefPubMed
14.
go back to reference Di Marco GS, Hausberg M, Hillebrand U, Rustemeyer P, Wittkowski W, Lang D, Pavenstädt H. Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol. 2008;294:F1381–7.CrossRefPubMed Di Marco GS, Hausberg M, Hillebrand U, Rustemeyer P, Wittkowski W, Lang D, Pavenstädt H. Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol. 2008;294:F1381–7.CrossRefPubMed
15.
go back to reference Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriguez M. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol. 2006;17:795–804.CrossRefPubMed Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriguez M. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol. 2006;17:795–804.CrossRefPubMed
16.
go back to reference Rutkowski M, Grzegorczyk K. Adverse effects of antioxidative vitamins. Int J Occup Med Environ Health. 2012;25:105–21.CrossRefPubMed Rutkowski M, Grzegorczyk K. Adverse effects of antioxidative vitamins. Int J Occup Med Environ Health. 2012;25:105–21.CrossRefPubMed
17.
go back to reference Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429–35.CrossRefPubMed Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429–35.CrossRefPubMed
18.
go back to reference Rodriguez M, Muñoz-Castañeda JR, Almaden Y. Therapeutic use of calcitriol. Curr Vasc Pharmacol. 2014;12:294–9.CrossRefPubMed Rodriguez M, Muñoz-Castañeda JR, Almaden Y. Therapeutic use of calcitriol. Curr Vasc Pharmacol. 2014;12:294–9.CrossRefPubMed
19.
go back to reference Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W. Independent association of low serum 25- hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168:1340–9. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W. Independent association of low serum 25- hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168:1340–9.
20.
go back to reference Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, Clarke A, Franco OH. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas. 2010;65:225–36.CrossRefPubMed Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, Clarke A, Franco OH. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas. 2010;65:225–36.CrossRefPubMed
21.
go back to reference Norman PE, Powell JT, Vitamin D and cardiovascular disease. Circ Res. 2014;114:379–93. Norman PE, Powell JT, Vitamin D and cardiovascular disease. Circ Res. 2014;114:379–93.
22.
go back to reference Messa P, Cozzolino M, Brancaccio D, Cannella G, Malberti F, Costanzo AM, di Luzio PU, Festa V, Gualberti G, Mazzaferro S, FARO Study Group. Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study. BMC Nephrol. 2015;16:11.CrossRefPubMedPubMedCentral Messa P, Cozzolino M, Brancaccio D, Cannella G, Malberti F, Costanzo AM, di Luzio PU, Festa V, Gualberti G, Mazzaferro S, FARO Study Group. Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study. BMC Nephrol. 2015;16:11.CrossRefPubMedPubMedCentral
23.
go back to reference Zheng Z, Shi H, Jia J, Li D, Lin S. Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol. 2013;14:199.CrossRefPubMedPubMedCentral Zheng Z, Shi H, Jia J, Li D, Lin S. Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol. 2013;14:199.CrossRefPubMedPubMedCentral
Metadata
Title
Vitamin E protects against extraskeletal calcification in uremic rats fed high fat diets
Authors
Rafael Rios
Ana I. Raya
Carmen Pineda
Mariano Rodriguez
Ignacio Lopez
Escolastico Aguilera-Tejero
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2017
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-017-0790-4

Other articles of this Issue 1/2017

BMC Nephrology 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.